Actinium Pharmaceuticals (ATNM) Total Non-Current Liabilities (2012 - 2021)
Actinium Pharmaceuticals (ATNM) posted quarterly Total Non-Current Liabilities of $5.8 million for Q4 2021, down 3.56% quarter-over-quarter from $6.1 million in Q4 2018.
Actinium Pharmaceuticals (ATNM) Total Non-Current Liabilities (2012 - 2021) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Total Non-Current Liabilities for 8 consecutive years, with $5.8 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Total Non-Current Liabilities changed N/A year-over-year to $5.8 million; the TTM figure through Dec 2021 stood at $5.8 million (changed N/A YoY), while the FY2021 annual figure was $5.8 million, changed N/A from the prior year.
- Total Non-Current Liabilities fell to $5.8 million in Q4 2021 per ATNM's latest filing, from $6.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6.1 million in Q4 2018 and bottomed at $3.5 million in Q3 2017.
- Historically, Total Non-Current Liabilities has averaged $4.7 million across 3 years, with a median of $4.7 million in 2017.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 136.8% in 2017 and fell as far as 10.19% in 2017.
- Actinium Pharmaceuticals' Total Non-Current Liabilities stood at $4.7 million in 2017, then soared by 30.33% to $6.1 million in 2018, then retreated by 3.56% to $5.8 million in 2021.
- Business Quant data shows ATNM's Total Non-Current Liabilities at $5.8 million in Q4 2021, $6.1 million in Q4 2018, and $4.1 million in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Actinium Pharmaceuticals | 34.85 Mn | 34.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 5.85 Mn |
| Dec 31, 2018 | 6.06 Mn |
| Sep 30, 2018 | 4.14 Mn |
| Jun 30, 2018 | 5.25 Mn |
| Dec 31, 2017 | 4.65 Mn |
| Sep 30, 2017 | 3.48 Mn |
| Jun 30, 2017 | 3.68 Mn |
| Mar 31, 2017 | 4.79 Mn |
| Dec 31, 2016 | 4.22 Mn |
| Sep 30, 2016 | 2.60 Mn |
| Jun 30, 2016 | 1.55 Mn |
| Mar 31, 2016 | 2.06 Mn |
| Dec 31, 2015 | 1.76 Mn |
| Sep 30, 2015 | 926,992.00 |
| Jun 30, 2015 | 1.13 Mn |
| Mar 31, 2015 | 1.75 Mn |
| Dec 31, 2014 | 2.78 Mn |
| Sep 30, 2014 | 2.01 Mn |
| Jun 30, 2014 | 1.29 Mn |
| Mar 31, 2014 | -12.57 Mn |